Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRIMI study in bladder-sparing chemoradiotherapy with nivolumab with or without ipilimumab for muscle-invasive bladder cancer
2023-509460-19-00Phase 2Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- Oct 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab, ipilimumab, mitomycin c and capecitabine in muscle-invasive bladder cancer (MIBC) and transitional cell carcinoma of the bladder (TCC) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoints: Toxicity and dose-limiting toxicity and Disease-free survival. Started Oct 2024; status: completed.
02
Drugs
03
Conditions
muscle-invasive bladder cancer (MIBC)transitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on 2023-509460-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509460-19-00.